When does NPH (Neutral Protamine Hagedorn) insulin peak?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

NPH Insulin Peak Action Time

NPH insulin peaks at approximately 4-6 hours after administration, making it particularly suitable for managing steroid-induced hyperglycemia when timed to coincide with the peak hyperglycemic effect of glucocorticoids. 1, 2

Pharmacokinetic Profile of NPH Insulin

  • NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin with onset, peak, and duration characteristics that differ significantly from other insulin formulations 1
  • The peak action of NPH insulin occurs approximately 4-6 hours after subcutaneous injection 2, 3
  • The total duration of action for NPH insulin is approximately 10-15 hours, though some studies have reported it lasting up to 13-25 hours 4, 5
  • Unlike long-acting insulin analogs such as insulin glargine which have a relatively peakless action profile, NPH has a distinct peak that must be considered when planning insulin regimens 4, 6

Clinical Applications Based on NPH Peak Timing

  • The American Diabetes Association recommends NPH insulin specifically for steroid-induced hyperglycemia because its peak action at 4-6 hours aligns with the peak hyperglycemic effect of morning-administered glucocorticoids 1, 2
  • For patients on once or twice-daily steroids, NPH insulin is the standard approach and should be administered concomitantly with intermediate-acting steroids to match their pharmacokinetic profiles 1
  • When using NPH for enteral nutrition coverage in hospitalized patients, the timing of administration should consider the 4-6 hour peak to coincide with nutritional load 1

Practical Considerations for Dosing

  • Due to NPH's peak action at 4-6 hours, there is an increased risk of hypoglycemia during this time period, especially in patients with poor oral intake 1
  • When NPH is administered at bedtime, the peak action occurring 4-6 hours later (middle of the night) can lead to nocturnal hypoglycemia, a significant clinical concern 7
  • For hospitalized patients receiving enteral nutrition, NPH can be administered every 8-12 hours (two or three times daily) to provide more consistent coverage throughout the day 1

Comparison with Other Insulin Formulations

  • Regular insulin peaks earlier than NPH, with studies showing peak action at approximately 2-5.7 hours after injection 5, 8
  • Long-acting insulin analogs like insulin glargine have a relatively peakless action profile lasting approximately 24 hours, making them more suitable for basal insulin coverage 4, 6
  • The distinct 4-6 hour peak of NPH makes it less ideal as a basal insulin compared to newer long-acting analogs, but more appropriate for specific clinical scenarios like steroid coverage 7

Important Considerations and Pitfalls

  • The peak action of NPH at 4-6 hours must be considered when planning meal timing and dosing schedules to avoid hypoglycemia 1
  • When using NPH for steroid coverage, it's essential to adjust the dose when steroids are tapered to prevent hypoglycemia 3
  • For patients requiring both basal and prandial coverage, NPH alone may be insufficient due to its peak action profile, and additional rapid-acting insulin may be needed 4
  • In older studies, NPH was found to have a peak effect at 4-19 hours (mean 11 hours), highlighting the potential variability in individual responses 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

NPH Insulin Regimen for Steroid-Induced Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Steroid-Induced Hyperglycemia with NPH Insulin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical strategies for controlling peaks and valleys: type 1 diabetes.

International journal of clinical practice. Supplement, 2002

Research

Time-action characteristics of regular and NPH insulin in insulin-treated diabetics.

The Journal of clinical endocrinology and metabolism, 1980

Research

Insulin Glargine: a review 8 years after its introduction.

Expert opinion on pharmacotherapy, 2009

Research

Insulin glargine versus NPH insulin in patients with type 1 diabetes.

Drugs of today (Barcelona, Spain : 1998), 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.